A263050 Stock Overview
Engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Eutilex.Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,868.00 |
| 52 Week High | ₩3,700.00 |
| 52 Week Low | ₩1,765.00 |
| Beta | 0.47 |
| 11 Month Change | -23.13% |
| 3 Month Change | -23.76% |
| 1 Year Change | -35.48% |
| 33 Year Change | -88.49% |
| 5 Year Change | -91.53% |
| Change since IPO | -92.82% |
Recent News & Updates
Despite Lacking Profits Eutilex.Co.Ltd (KOSDAQ:263050) Seems To Be On Top Of Its Debt
Aug 07
Is Eutilex.Co.Ltd (KOSDAQ:263050) A Risky Investment?
Apr 15Shareholder Returns
| A263050 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -8.4% | -0.03% | -1.2% |
| 1Y | -35.5% | 21.0% | -6.7% |
Return vs Industry: A263050 underperformed the KR Biotechs industry which returned 21% over the past year.
Return vs Market: A263050 underperformed the KR Market which returned -6.6% over the past year.
Price Volatility
| A263050 volatility | |
|---|---|
| A263050 Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.8% |
Stable Share Price: A263050's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A263050's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 94 | Byoung S. Kwon | www.eutilex.com |
Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies.
Eutilex.Co.,Ltd Fundamentals Summary
| A263050 fundamental statistics | |
|---|---|
| Market cap | ₩68.73b |
| Earnings (TTM) | -₩25.34b |
| Revenue (TTM) | ₩6.89b |
10.0x
P/S Ratio-2.7x
P/E RatioIs A263050 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A263050 income statement (TTM) | |
|---|---|
| Revenue | ₩6.89b |
| Cost of Revenue | ₩5.91b |
| Gross Profit | ₩981.11m |
| Other Expenses | ₩26.32b |
| Earnings | -₩25.34b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -688.74 |
| Gross Margin | 14.23% |
| Net Profit Margin | -367.62% |
| Debt/Equity Ratio | 14.9% |
How did A263050 perform over the long term?
See historical performance and comparison